1 published article · Updated continuously
22 trials tracked for Neisseria meningitidis: 13 in phase 3 or 4 and 1 with published results. The most-cited published study has 16 citations.
Showing the 22 most-cited and recently-updated of 22 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Several conjugate vaccines against Neisseria meningitidis have demonstrated robust immunogenicity in infants and toddlers. The combined Hib-MenCY-TT vaccine (MenHibrix) elicited anti-PRP antibody concentrations ≥1.0 µg/mL in 98.2% to 98.8% of subjects after the primary series 419. Similarly, the combined Hib-MenC-TT vaccine (Menitorix) induced anti-PRP ≥0.15 µg/mL in a high proportion of subjects 112. The quadrivalent meningococcal conjugate vaccine Menactra (A, C, Y, W-135) produced at least a 4-fold rise in serum bactericidal antibody titers in 57% to 86% of participants across serogroups 9. Another combined vaccine (PR5I) achieved 100% seroprotection against PRP (≥0.15 µg/mL) and high responses to diphtheria, tetanus, and poliovirus antigens 2. The investigational vaccine V419 also showed 100% of participants with anti-MCC titers ≥1:8 after one dose 3.
The combination of Hib and meningococcal serogroup C vaccines (e.g., Menitorix) consistently induced protective anti-PRP antibodies. In one study, 98.9% of infants had anti-PRP ≥0.15 µg/mL after three doses 3. Another trial reported that 100% of subjects achieved anti-PRP ≥0.15 µg/mL after vaccination with a combined Hib-MenC-TT vaccine 13. The Hib-MenCY-TT vaccine also demonstrated high immunogenicity against both Hib and meningococcal serogroups C and Y, with anti-PRP ≥1.0 µg/mL in over 97% of subjects 419. These findings support the use of combination vaccines to simplify the immunization schedule while maintaining strong immune responses.
AI synthesis of 13 cited trials, updated Jun 26, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
